Low-dose rapamycin treatment increases the ability of human regulatory T cells to inhibit transplant arteriosclerosis in vivo.

Regulatory T cells (T(reg)) are currently being tested in clinical trials as a potential therapy in cell and solid organ transplantation. The immunosuppressive drug rapamycin has been shown to preferentially promote T(reg) expansion. Here, we hypothesized that adjunctive rapamycin therapy might pote...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy: Hester, J, Schiopu, A, Nadig, SN, Wood, K
Format: Journal article
Język:English
Wydane: 2012